Tuberculosis complicating treatment of hepatitis C in an HIV-infected haemophilia A patient.
Pegylated interferon (pegIFN)/ribavirin has been established as the treatment of choice for chronic hepatitis C in HIV co-infected individuals [1-3]. We report the case of an individual who was well prior to treatment, but was diagnosed with tuberculous adenitis after receiving 12 weeks of pegIFN/ribavirin therapy. The association of pegIFN and ribavirin therapy with tuberculosis (TB) has not been described previously.
Killingley
B
B
Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK. bkillingley@hotmail.com
Bhagani
S
S
Slapak
G
G
Yee
T T
TT
Johnson
M
M
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects; D015658:HIV Infections / Q000150:complications*; D006467:Hemophilia A / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D008199:Lymphadenitis / Q000139:chemically induced*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects; D016896:Treatment Outcome; D014388:Tuberculosis, Lymph Node / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a